Compare Agilent Technologies Inc (A) vs Chewy Inc (CHWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Chewy Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Chewy Inc trades at $22.4 (market cap $9.25B). The key difference: Agilent Technologies Inc is far larger — about 4.5× Chewy Inc's market cap, and Agilent Technologies Inc pays a 0.69% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| A | CHWY | |
|---|---|---|
Market Cap | $42.00B | $9.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $42.33 |
52-Week Low | $110.24 | $17.51 |
Enterprise Value | $43.55B | $9.21B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
Chewy (CHWY) trades at $23.53, up 0.43% with a bullish technical signal supported by moving averages. The company shows strong revenue growth from $8.9B in 2022 to $11.86B in 2025, with net income turning positive at $393M. Recent earnings beat expectations in Q1 2026 with EPS of $0.43 versus $0.24 expected. Analyst consensus remains strongly bullish with 81.58% buy ratings and a $33.82 price target, representing 44% upside potential from current levels.
Chewy's outlook appears favorable with expanding veterinary services and Autoship subscription model driving recurring revenue. Key risks include competitive pressure from Amazon and Walmart, insider selling activity, and margin compression as net income margin is projected to decline to 1.98% in 2026. The stock offers growth potential but requires monitoring of execution against aggressive expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →
